Hikma Pharmaceuticals Plc Block Listing of Shares (6374A)

TIDMHIK

RNS Number : 6374A

Hikma Pharmaceuticals Plc

21 February 2014

Block Listing of Shares

Hikma PharmaceuticalsPLC

LONDON, 21 February 2014 - The Board of Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (NASDAQ: HIK), announces that it has made a block listing application to the Financial Conduct Authority and the London Stock Exchange plc for a total of 500,000 ordinary shares of 10p each in the capital of the Company to be admitted to the Official List of the UK Listing Authority. It is expected that admission will be granted on 24 February 2014.

The shares, when issued, will be issued fully paid and rank pari passu in all respects with the existing issued ordinary shares of the Company. The shares will be issued pursuant to the vesting of shares under the Hikma Pharmaceuticals PLC 2005 Long Term Incentive Plan and the 2009 Management Incentive Plan (the "Plans"). Participants in the Plans have or will become entitled to these shares following the vesting of the shares.

- ENDS -

Enquiries

 
 Hikma Pharmaceuticals 
  PLC 
 Peter Speirs 
  Company Secretary       +44 20 7399 2760

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2012, Hikma achieved revenues of $1,108.7 million and profit attributable to shareholders of $100.3 million.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BLRSEDFSFFLSEEE

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024